Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Employees - 1,
CEO - Mr. Tomer Izraeli,
Sector - Healthcare,
Country - IL,
Market Cap - 6.34M
| Ticker | PLRZ |
| Index | - |
| Curent Price | 1.57 |
| Change | -32.62% |
| Market Cap | 6.34M |
| Average Volume | 4.26M |
| Income | -1.00M |
| Sales | 0.00M |
| Book Value/Share | -0.01 |
| Cash/Share | 0.00 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | - |
| Moving Avg 20days | 28.31% |
| Moving Avg 50days | 34.35% |
| Moving Avg 200days | 34.35% |
| Shares Outstanding | 4.04M |
| Earnings Date | - |
| Inst. Ownership | - |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | - |
| Price/Cash | 317.14 |
| Price/FCF | - |
| Quick Ratio | 0.12 |
| Current Ratio | 0.12 |
| Debt/Equity | 0.68 |
| Return on Assets | -108.60% |
| Return on Equity | - |
| Return on Investment | -449.10% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 52.40 |
| BETA(β) | - |
| From 52week Low | 103.90% |
| From 52week High | -67.29% |
| EPS | -0.25 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | - |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -163.74% |
| Sales Y/Y | - |
| EPS Q/Q | -208.05% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | - |
| ATR(14) | 0.56 |
| Perf Week | 58.43% |
| Perf Month | 66.14% |
| Perf Quarter | - |
| Perf Year | - |
| Perf YTD | 1.29% |
| Target Price | - |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer